Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + XELOX in advanced gastrointestinal neuroendocrine carcinoma
NCT06070740Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2023
- Primary completion
- Nov 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in gastrointestinal neuroendocrine carcinoma (GI-NEC), sponsored by Peking Union Medical College Hospital. Started Nov 2023; status: recruiting.
02
Drugs
durvalumab
03
Conditions
gastrointestinal neuroendocrine carcinoma (GI-NEC)
Beyond the preview
Go deeper on NCT06070740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06070740.